- Archaeological perception of geophysical data more
- Archaeology and anthropology in a world of hybrids, cyborgs and posthumans more
- Archive stereo-aerial photographs for reconstructing archaeological earthworks more
- Are Dominant Males More Successful Reproductively? more
- Are immersive FPS games enjoyable? more
- Are newer female sex workers (FSWs) more vulnerable to HIV ? Comparison of key behavioural indicators from integrated biological and behavioural surveillance (IBBS) survey among FSWs in Kathmandu more
- Are patients with Parkinson’s disease who have either mild to moderate microsmia, severe microsmia or anosmia clinically different? more
- Are Photogrammetry and 3D Scanning a real alternative to 3D modelling for Virtual Heritage applications? more
- Are student midwives equipped to support normal birth? more
- ARE SWEETNESS PREFERENCES MODIFIABLE? THE DEVELOPMENT OF THE PRIMARY OUTCOME VARIABLE TO ASSESS THE EFFECTS OF SWEETNESS EXPOSURE ON PREFERENCES more
- Are there differences in cervical inter-vertebral laxity or translation motion between patients with neck pain and healthy controls? more
- Are UK Nature Conservation Laws Fit for Purpose? more
- Are UK universities marketing themselves effectively to UK blue chip employers? more
- Are UK universities more ethical than police organisations? more
- Are We Raising Media Critics or Cynics? more
- Are we there yet? more
- Are we there yet? more
- Are Web Development Methods Too Difficult To Use? more
- Are You There: Material and Immaterial more
- Are You There: the relationship between film and screen more
- ARElight: Context Sampling of Large Texts for Deep Learning Relation Extraction more
- Arsenic in the bengal delta plain: Geochemical complications and potential mitigation option more
- Art in corporate governance: A Deweyan perspective on board experience more
- ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer: primary endpoint – pathological complete response (pCR) more
- ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer: primary endpoint – pathological complete response (pCR). more